GlassScriptPhysician profile
Tamar Harel
NPI 1497288831
$2,510.11
in general payments reported to CMS, 2019-2025
21 companies · $382 in 2025
The $382 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $354 · 2024: $1,774 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,452 · Education: $58.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,451.61 |
| Education | $58.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $487.81 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $442.71 | 2023-2025 | |
| Tg Therapeutics, INC. | $288.77 | 2023-2025 | |
| Emd Serono, INC. | $272.90 | 2024-2025 | |
| Amgen INC. | $177.04 | 2024 | Uplizna |
| Alexion Pharmaceuticals, INC. | $142.40 | 2024 | Ultomiris |
| Genentech USA, INC. | $113.14 | 2024 | Ocrevus, Ocrevus Zunovo |
| Ucb, INC. | $89.80 | 2024-2025 | Briviact, Rystiggo, Zilbrysq |
| Celgene Corporation | $73.79 | 2024 | Zeposia |
| Biogen, INC. | $61.69 | 2023 | Tysabri, Vumerity, Plegridy |
| Lundbeck LLC | $57.64 | 2025 | Rexulti, Vyepti |
| Neurelis, INC. | $53.19 | 2023-2024 | Valtoco |
| Eisai INC. | $48.13 | 2024-2025 | |
| Horizon Therapeutics Plc | $45.93 | 2023 | Uplizna |
| Genzyme Corporation | $43.55 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $28.50 | 2024 | Hizentra |
| Neurocrine Biosciences, INC. | $19.25 | 2024 | Ingrezza |
| Lilly USA, LLC | $18.92 | 2024 | Kisunla |
| Sumitomo Pharma America, INC. | $15.72 | 2024 | Gemtesa |
| Revance Therapeutics, INC. | $15.37 | 2024 | Daxxify |
| Pfizer INC. | $13.86 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamar Harel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.